Actively Recruiting
Study Evaluating Intravenous NGGT002 Gene Therapy in Adults with Phenylketonuria
Led by NGGT (Suzhou) Biotechnology Co., Ltd. · Updated on 2026-08-13
18
Participants Needed
2
Research Sites
147 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effects of NGGT002, a gene therapy treatment, in adults with classic Phenylketonuria PKU, a condition caused by severe deficiency of the PAH enzyme. This Phase 12 study involves multiple centers and focuses on adults aged 18 to 55 years who carry specific genetic variants causing PKU. The trial aims to understand how well NGGT002 works and its safety when given as a single dose. Participants receive one intravenous infusion of NGGT002, which uses a viral vector to deliver a functional PAH gene. The study includes three groups receiving different dose levels, with 6 to 18 patients enrolled across these groups. After treatment, participants are followed for safety and effectiveness over a period of five years to monitor long-term outcomes. During the study, participants will have blood tests to measure plasma phenylalanine Phe levels at various points up to one year, and their diet and quality of life will be assessed. Researchers will track any side effects and changes in Phe concentrations, as well as dietary intake and PKU-related quality of life scores. Regular monitoring will support understanding of both safety and treatment impact over the long term.
CONDITIONS
Brief Title
Safety and Efficacy Study of NGGT002 in Adult Patients With Phenylketonuria
Research Team
H
Huan Zhou, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here